Treatment Intensification in Metastatic Hormone-Sensitive Prostate Cancer
PROSTAID Calgary’s 2022 Pathfinder Award went to Dr. Geoffrey Gotto, who presented on new research and innovations in metastatic castration-sensitive prostate cancer (MCSPC) that is leading to longer survival and greater quality of life in prostate cancer patients who do combinations of treatments to combat the cancer.